Table 9 The drug release profile of Pure FNO, Formulation containing co-crystal (CCT) and Marketed formulation (n = 3, mean ± SD)
From: Particle engineering of fenofibrate for advanced drug delivery system
Time | % drug release of Pure drug | % drug release of Formulation containing Co-crystal(CCT) | % drug release of Marketed |
|---|---|---|---|
0 | 0 | 0 | 0 |
5 | 0.676±0.555 | 0.926±0.325 | 2.786±0.325 |
15 | 1.986±0.642 | 7.364±1.024 | 4.987±0.554 |
30 | 2.109±0.552 | 15.998±1.554 | 7.988±0.685 |
45 | 2.768±0.578 | 23.987±2.055 | 10.766±0.885 |
60 | 3.654±0.702 | 32.986±3.688 | 14.559±1.525 |
120 | 10.39±0.924 | 69.67±5.326 | 21.618±3.544 |